Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.800
Open
1.800
VWAP
1.70
Vol
837.47K
Mkt Cap
107.88M
Low
1.640
Amount
1.43M
EV/EBITDA(TTM)
--
Total Shares
62.63M
EV
-93.78M
EV/OCF(TTM)
--
P/S(TTM)
0.71
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
FY2025Q1
22.63M
-79.56%
--
--
11.77M
+8.99%
--
--
9.59M
+5.37%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for MacroGenics, Inc. (MGNX) for FY2025, with the revenue forecasts being adjusted by 7.85% over the past three months. During the same period, the stock price has changed by -47.06%.
Revenue Estimates for FY2025
Revise Upward
+7.85%
In Past 3 Month
Stock Price
Go Down
-47.06%
In Past 3 Month
6 Analyst Rating
250.88% Upside
Wall Street analysts forecast MGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGNX is 6.00 USD with a low forecast of 2.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
4 Hold
0 Sell
Moderate Buy
250.88% Upside
Current: 1.710
Low
2.00
Averages
6.00
High
8.00
250.88% Upside
Current: 1.710
Low
2.00
Averages
6.00
High
8.00
HC Wainwright & Co.
Robert Burns
Hold
Maintains
$4 → $2
2025-03-25
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$4 → $2
2025-03-25
Maintains
Hold
Reason
JMP Securities
Silvan Tuerkcan
Buy
to
Hold
Downgrades
n/a
2024-11-07
Reason
JMP Securities
Silvan Tuerkcan
Price Target
n/a
2024-11-07
Downgrades
Buy
to
Hold
Reason
JMP Securities analyst Silvan Tuerkcan downgraded MacroGenics to Market Perform from Outperform without a price target. The company "is in a holding pattern" with respect to its pipeline, has paused all vobra duo development, including the lorigerlimab combo, and sold Margenza, the analyst tells investors in a research note. The firm cites the uncertain future of MacroGenics' B7-H3 franchise and lack of data and clarity on lorigerlimab and the DART programs for the downgrade. It views the shares as fairly valued currently.
HC Wainwright & Co.
Robert Burns
Hold
Reiterates
$4
2024-11-06
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$4
2024-11-06
Reiterates
Hold
Reason
HC Wainwright & Co.
Robert Burns
Hold
Reiterates
$4
2024-09-18
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$4
2024-09-18
Reiterates
Hold
Reason
HC Wainwright & Co.
Robert Burns
Hold
Reiterates
$4
2024-08-21
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$4
2024-08-21
Reiterates
Hold
Reason
Citigroup
Yigal Nochomovitz
Strong Buy
Maintains
$16 → $14
2024-08-15
Reason
Citigroup
Yigal Nochomovitz
Price Target
$16 → $14
2024-08-15
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for MacroGenics Inc (MGNX.O) is -0.67, compared to its 5-year average forward P/E of -4.48. For a more detailed relative valuation and DCF analysis to assess MacroGenics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.48
Current PE
-0.67
Overvalued PE
0.88
Undervalued PE
-9.85
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.87
Current EV/EBITDA
0.49
Overvalued EV/EBITDA
-0.11
Undervalued EV/EBITDA
-7.63
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
6.64
Current PS
1.81
Overvalued PS
11.79
Undervalued PS
1.50
Financials
Annual
Quarterly
FY2024Q4
YoY :
+80.53%
19.35M
Total Revenue
FY2024Q4
YoY :
+7.06%
-52.84M
Operating Profit
FY2024Q4
YoY :
-66.53%
-15.42M
Net Income after Tax
FY2024Q4
YoY :
-66.22%
-0.25
EPS - Diluted
FY2024Q4
YoY :
+36.19%
-39.03M
Free Cash Flow
FY2024Q4
YoY :
-27.26%
71.63
Gross Profit Margin - %
FY2024Q4
YoY :
-64.69%
-48.06
FCF Margin - %
FY2024Q4
YoY :
-81.46%
-79.68
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
550.0K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
164.9K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
4
1.2M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MGNX News & Events
Events Timeline
2024-11-05 (ET)
2024-11-05
15:14:00
MacroGenics reports Q3 EPS 90c, consensus 21c
2024-10-30 (ET)
2024-10-30
07:32:55
MacroGenics announces CEO Koenig to step down
2024-10-22 (ET)
2024-10-22
07:40:20
MacroGenics in $40M deal with TerSera Therapeutics for sale of Margenza
Sign Up For More Events
Sign Up For More Events
News
4.0
03-24Business InsiderAnalysts Offer Insights on Healthcare Companies: Immunome (IMNM), Sanofi (OtherSNYNF) and MacroGenics (MGNX)
8.5
03-24BenzingaWhy AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
4.0
03-20Business InsiderMacroGenics (MGNX) Gets a Hold from TD Cowen
Sign Up For More News
People Also Watch
CLFD
Clearfield Inc
29.140
USD
+2.10%
VZLA
Vizsla Silver Corp
2.170
USD
-2.25%
EBS
Emergent BioSolutions Inc
5.490
USD
+2.23%
EBF
Ennis Inc
17.920
USD
-0.78%
HUMA
Humacyte Inc
1.440
USD
-2.70%
CMTG
Claros Mortgage Trust Inc
2.430
USD
+0.83%
LASR
nLIGHT Inc
7.820
USD
+0.90%
NYMT
New York Mortgage Trust Inc
5.640
USD
+0.89%
QD
Qudian Inc
2.650
USD
0.00%
TMCI
Treace Medical Concepts Inc
6.720
USD
+0.90%
FAQ
What is MacroGenics Inc (MGNX) stock price today?
The current price of MGNX is 1.71 USD — it has decreased -4.47 % in the last trading day.
What is MacroGenics Inc (MGNX)'s business?
What is the price predicton of MGNX Stock?
What is MacroGenics Inc (MGNX)'s revenue for the last quarter?
What is MacroGenics Inc (MGNX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for MacroGenics Inc (MGNX)'s fundamentals?
How many employees does MacroGenics Inc (MGNX). have?